Libros importados hasta 50% OFF + Envío Gratis a todo USA  Ver más

menu

0
  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional
portada Health Care: Adrenal Cortical Extract Taken Off Drug Market: Hrd-81-61 (in English)
Type
Physical Book
Publisher
Language
Inglés
Pages
44
Format
Paperback
Dimensions
24.6 x 18.9 x 0.2 cm
Weight
0.10 kg.
ISBN13
9781289000677

Health Care: Adrenal Cortical Extract Taken Off Drug Market: Hrd-81-61 (in English)

U. S. Government Accountability Office ( ; U. S. Government Accountability Office ( (Author) · Bibliogov · Paperback

Health Care: Adrenal Cortical Extract Taken Off Drug Market: Hrd-81-61 (in English) - U. S. Government Accountability Office ( ; U. S. Government Accountability Office (

Physical Book

$ 13.26

$ 15.75

You save: $ 2.49

16% discount
  • Condition: New
It will be shipped from our warehouse between Thursday, August 01 and Friday, August 02.
You will receive it anywhere in United States between 1 and 3 business days after shipment.

Synopsis "Health Care: Adrenal Cortical Extract Taken Off Drug Market: Hrd-81-61 (in English)"

Adrenal cortical extract (ACE) products were once recommended in the treatment of Addison's disease and for several other indications including hypoglycemia. In January 1978, the Food and Drug Administration (FDA) advised drug firms marketing ACE products that the drug represented a substantial risk of undertreatment because of its low potency and the resulting potential hazard to patients. A review of current well-known textbooks on medicine and endocrinology showed a unanimous preference for using synthetic compounds in the treatment of both the chronic and acute phases of Addison's disease. GAO could not find any medical support for using ACE products in the treatment of hypoglycemia. The regulatory actions taken by FDA against ACE were within its legal authority under the Food, Drug, and Cosmetic Act and were not unreasonable. The use of alternative procedures would have afforded all interested parties a better opportunity to comment on FDA findings and proposed actions; however, the affected drug firms had an opportunity to challenge FDA findings and did not.

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

All books in our catalog are Original.
The book is written in English.
The binding of this edition is Paperback.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews